Breaking News Instant updates and real-time market news.

MACK

Merrimack

$6.35

0.09 (1.44%)

07:18
10/03/16
10/03
07:18
10/03/16
07:18

Merrimack announces 22% reduction in headcount, CEO Mulroy resigns

Merrimack Pharmaceuticals announced a major corporate restructuring with the objective of prioritizing its research and development on a focused set of systems biology-derived oncology products and strengthening its financial runway. As part of this move, Merrimack is immediately implementing a 22% reduction in headcount and eliminating more than $200M in expected costs over the next two years. In line with this restructuring, the Board of Directors has accepted the resignation of President and CEO Robert Mulroy, effective immediately. In order to accelerate this change, the Board of Directors has appointed Chairman of the Board Gary Crocker as interim President and CEO. "The Board is committed to focusing our resources. This major restructuring will allow us to strategically align our pipeline with our core capabilities and prioritize ongoing clinical development efforts while improving our financial flexibility," stated Crocker. "We believe this sharper focus will drive efficiency and innovation and promote the interests of not only our shareholders and employees, but also of cancer patients worldwide. The realization of shareholder value will become as intense a focus for Merrimack as our strength in innovation and development. The Board is convinced that there is tremendous inherent value within Merrimack that can be unlocked." In line with delivering the new goals of innovation and efficiency, John Dineen, Chairman of the Organization and Compensation Committee and former CEO of GE Healthcare, will lead the CEO search process. "We are grateful to Bob and acknowledge his leadership of Merrimack over the years," said Dineen. The reduction in personnel will not impact the commercial team or the execution of ONIVYDE's commercial launch and label expansion. "This strategic shift is designed to align our resources with the programs that have the greatest potential for disruptive change in the diagnosis and treatment of cancer, as well as to significantly increase our financial flexibility," said Dr. Yasir Al-Wakeel, CFO and Head of Corporate Development. He adds, "With the elimination of more than $200 million in expected expenses through research and development efficiencies, prioritization and cost containment over the next two years, today's announcement places Merrimack in a much stronger financial position." As a result, Merrimack now anticipates aggregate research and development and selling, general and administrative expenses in 2017 of approximately $190 million when calculated in accordance with GAAP, resulting in a cash runway that is expected to fund operations for at least the next 12 months based on cash on hand, anticipated near term milestones and reimbursements and ONIVYDE profits. This corresponds to a non-GAAP financial measure of $165 million of aggregate research and development and selling, general and administrative expenses in 2017 when excluding $25 million of anticipated milestone obligations to PharmaEngine, which are fully offset by corresponding milestone achievement obligations from Shire. A table reconciling guidance for aggregate research and development and selling, general and administrative expenses, excluding anticipated milestone obligations to PharmaEngine, a non-GAAP financial measure, to aggregate research and development and selling, general and administrative expenses calculated in accordance with GAAP is included at the end of this press release. The reduction in force was substantially completed on October 3rd and is expected to be fully completed by December 3rd. More information on the restructuring will be available in the Form 8-K to be filed by Merrimack. Merrimack plans to provide more financial and strategic details regarding the conclusion of this product prioritization process by the end of the fourth quarter.

MACK Merrimack
$6.35

0.09 (1.44%)

08/04/16
08/04/16
NO CHANGE

On The Fly: After Hours Movers
UP AFTER EARNINGS: Pacific Biosciences (PACB), up 17%... MasTec (MTZ), up 9.6%... Aratana Therapeutics (PETX), up 9.2%... Lion's Gate (LGF), up 6.4%... Priceline (PCLN), up 5.7%... Ubiquiti (UBNT), up 5.5%... MercadoLibre (MELI), up 4.1%... Organovo (ONVO), up 3.9%... Kraft Heinz (KHC), up 3.3%... EOG Resources (EOG), up 2.8%... Monster Beverage (MNST), up 1.2%... TASER (TASR), up 1.2%... Take-Two (TTWO), up 0.9%... Activision Blizzard (ATVI), up 1%... BioMarin (BMRN), up 0.4%. ALSO HIGHER: Egalet (EGLT), up 31.2% after the company announced that an FDA advisory committee recommended approval of its ARYMO ER drug... Rackspace (RAX), up 17.6% after the Wall Street Journal reported that the company was near a takeover deal with a private equity buyer... Osiris (OSIR), up 8.5% after it said that the manuscript from its prospective trial using Grafix was published. DOWN AFTER EARNINGS: Hortonworks (HDP), down 26.2%... PDL BioPharma (PDLI), down 17.5%... FireEye (FEYE), down 15.8%... Sierra Wireless (SWIR), down 15.6%... Aquinox (AQXP), down 14.7%... Zynga (ZNGA), down 9.4%... Universal Display (OLED), down 8.2%... Weight Watchers (WTW), down 7.6%... Zillow Group (Z, ZG), down 5.5%... Arista Networks (ANET), down 4.5%... Noodles & Company (NDLS), down 4.3%... Merrimack (MACK), down 1.7%... Bankrate (RATE), down 1.7%.
08/05/16
BMUR
08/05/16
NO CHANGE
Target $13
BMUR
Buy
Merrimack price target lowered to $13 from $16 at Brean Capital
Brean Capital lowered its price target on Merrimack to $13 from $16 following Q2 results. The firm cited the sales miss on Onivyde, although they are encouraged by its early launch. Brean Capital reiterated its Buy rating on Merrimack shares.
08/05/16
COWN
08/05/16
DOWNGRADE
COWN
Market Perform
Merrimack downgraded to Market Perform from Outperform at Cowen
08/19/16
BTIG
08/19/16
INITIATION
BTIG
Neutral
Merrimack initiated with a Neutral at BTIG
BTIG analyst Ling Wang initiated Merrimack with a Neutral as he expects shares to be range-bound given the likely slow ramp-up of ONIVYDE and data from MM-302 and MM-121 won't be available until 2017 or beyond;

TODAY'S FREE FLY STORIES

B

Barnes Group

$55.08

1.83 (3.44%)

15:59
04/28/17
04/28
15:59
04/28/17
15:59
Downgrade
Barnes Group rating change  »

Correction: Barnes Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

AZRX

AzurRx BioPharma

$3.51

-0.04 (-1.13%)

15:54
04/28/17
04/28
15:54
04/28/17
15:54
Hot Stocks
Breaking Hot Stocks news story on AzurRx BioPharma »

Matthew Balk reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMF

OneMain Holdings

$23.36

-1.26 (-5.12%)

15:51
04/28/17
04/28
15:51
04/28/17
15:51
Options
Opening action in OneMain Holdings puts as shares drop »

Opening action in OneMain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 25

    May

CHFC

Chemical Financial

$47.97

-0.79 (-1.62%)

15:50
04/28/17
04/28
15:50
04/28/17
15:50
Upgrade
Chemical Financial rating change  »

Chemical Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

BOFI

BofI Holding

$24.76

0.52 (2.15%)

15:46
04/28/17
04/28
15:46
04/28/17
15:46
Options
BofI Holding call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 30

    May

ADI

Analog Devices

$77.85

-0.13 (-0.17%)

15:36
04/28/17
04/28
15:36
04/28/17
15:36
Options
Analog Devices put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

MDXG

MiMedx

$11.40

0.3 (2.70%)

15:32
04/28/17
04/28
15:32
04/28/17
15:32
Recommendations
MiMedx analyst commentary  »

MiMedx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 06

    Jun

GST

Gastar Exploration

$1.31

0.01 (0.77%)

15:30
04/28/17
04/28
15:30
04/28/17
15:30
Conference/Events
Gastar Exploration to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 05

    May

CLVS

Clovis

$58.21

-0.43 (-0.73%)

15:26
04/28/17
04/28
15:26
04/28/17
15:26
Options
Clovis call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

$NSD

NASDAQ Market Internals

15:17
04/28/17
04/28
15:17
04/28/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIG

Fortress

$8.04

0.005 (0.06%)

, SFTBF

SoftBank

$75.60

0.71 (0.95%)

15:17
04/28/17
04/28
15:17
04/28/17
15:17
Periodicals
Fortress exploring sale of Logan Circle bond fund unit, Reuters says »

Fortress Investment Group…

FIG

Fortress

$8.04

0.005 (0.06%)

SFTBF

SoftBank

$75.60

0.71 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
04/28/17
04/28
15:16
04/28/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
04/28/17
04/28
15:15
04/28/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

CAG

Conagra Brands

$38.82

0.005 (0.01%)

15:11
04/28/17
04/28
15:11
04/28/17
15:11
Options
Downside put buyer in Conagra Foods »

Downside put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAH

Cardinal Health

$72.36

-0.78 (-1.07%)

15:10
04/28/17
04/28
15:10
04/28/17
15:10
Initiation
Cardinal Health initiated  »

Cardinal Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

FIG

Fortress

$8.04

0.01 (0.12%)

15:04
04/28/17
04/28
15:04
04/28/17
15:04
Periodicals
Breaking Periodicals news story on Fortress »

Fortress exploring sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$9.06

0.03 (0.33%)

15:01
04/28/17
04/28
15:01
04/28/17
15:01
Options
Sprint calls active ahead of earnings next week »

Sprint calls active ahead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

GME

GameStop

$22.80

-0.3 (-1.30%)

14:56
04/28/17
04/28
14:56
04/28/17
14:56
Options
GameStop put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 31

    May

BSX

Boston Scientific

$26.43

0.25 (0.95%)

14:55
04/28/17
04/28
14:55
04/28/17
14:55
Recommendations
Boston Scientific analyst commentary  »

Boston Scientific price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 07

    Jun

  • 27

    Jun

TKPYY

Takeda Pharmaceutical Co. Ltd.

$23.98

0.05 (0.21%)

14:51
04/28/17
04/28
14:51
04/28/17
14:51
Hot Stocks
FDA grants accelerated approval to Takeda's brigatinib »

On April 28, 2017, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$39.76

-0.34 (-0.85%)

14:48
04/28/17
04/28
14:48
04/28/17
14:48
Conference/Events
The Progressive Corporation to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVO

Cenveo

$4.39

0.095 (2.21%)

14:48
04/28/17
04/28
14:48
04/28/17
14:48
Hot Stocks
Breaking Hot Stocks news story on Cenveo »

Nathu Ram Puri reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

BMY

Bristol-Myers

$56.01

0.34 (0.61%)

14:42
04/28/17
04/28
14:42
04/28/17
14:42
Hot Stocks
Bristol-Myers announces European Commission approval of Opdivo »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 06

    Jun

TAP

Molson Coors

$95.84

0.06 (0.06%)

14:41
04/28/17
04/28
14:41
04/28/17
14:41
Conference/Events
Molson Coors to hold an earnings follow-up conference call »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

IWM

iShares Trust Russell 2000 Index Fund

$139.37

-1.58 (-1.12%)

, RUT

Russell 2000 Index

14:40
04/28/17
04/28
14:40
04/28/17
14:40
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT)…

IWM

iShares Trust Russell 2000 Index Fund

$139.37

-1.58 (-1.12%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.